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Objective: Takayasu arteritis (TA) is an immune-mediated disease with an unknown etiology. Assessment of disease
activity in patients with TA is challenging owing to the absence of reliable serologic markers. Because circulation levels of
acute-phase proteins fluctuate with the severity and extent of the inflammatory reaction, theymay be potential biomarkers
for the identification of TA activity. To test this hypothesis, certain acute-phase proteins were examined in TA patients
and controls.
Methods: The study included 43 prospectively selected TA patients, with 18 in active phase and 25 in inactive phase. The
Sharma modified criteria were used for disease diagnosis, and the National Institutes of Health criteria were used for TA
activity assessment. Circulation levels of acute-phase proteins, including serum amyloid A (SAA), fibrinogen, complement
C4-binding protein (C4BP), C-reactive protein, serum amyloid P, haptoglobin, -acid glycoprotein, transthyretin,
1-microglobin, and complement fraction C3c and C4a were investigated by enzyme-linked immunosorbent assay in
each participant.
Results: Circulating levels of SAA and C4BP were significantly increased in active TA patients compared with inactive TA
patients and in controls, with (SAA: 95.9 [interquartile range, 51.9] vs 49.2 [82.0], P  .009; and 23.9 [50.1] mg/L,
P .001, respectively; C4BP: 88.5 [72.6] vs 61.7 [57.7], P .023; and 32.6 [32.1] mg/L, P< .001, respectively). The
levels of both proteins in inactive TA patients were still higher than those in controls (SAA: 49.2 [82.0] vs 23.9 [50.1]
mg/L, P  .021; C4BP: 61.7 [57.7] vs 32.6 [32.1] mg/L, P  .025). No difference was found in the levels of the other
acute-phase proteins studied.
Conclusions: SAA and C4BP may be useful biomarkers in determining the disease activity of TA. More work should be
done to test these results in a large cohort of patients in a longitudinal manner. ( J Vasc Surg 2010;51:700-6.)
Clinical Relevance:Disease activity assessment in patients with Takayasu arteritis is important but difficult because of the
absence of reliable serologic markers. The concentration of acute-phase proteins, a group of liver-derived plasma proteins,
changes greatly in inflammatory disease. This study investigated the circulation levels of acute-phase proteins in Takayasu
arteritis patients with different disease activity and in healthy controls and evaluated their possibility as biomarkers for
activity judgment in this disease.Takayasu arteritis (TA) is a rare, chronic inflamma-
tory vasculitis that mainly affects the large elastic arteries,
such as the aortic arch and its primary branches, leading
to stenosis, occlusion, or aneurysm formation in vessels.1
Infectious agents, autoimmunity, and genetic factors are
considered to play a major role in the physiopathology of
this disease.2
In the natural course of TA, the patient experiences
cycles of active and inactive phases that reflect the different
inflammatory states of the arterial lesions. Treatment strat-
egies of the two phases are quite different. In the active
phase, immunosuppressive and cytotoxic agents are usually
used to control the development of inflammation, relieve
the symptoms, and restrict the extent of affected arteries.
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700The aim during the inactive phase, however, is to closely
monitor disease activity. Any necessary vascular recon-
structive operations or endovascular interventions are per-
formed preferably in this phase.3,4 Clinicians must carefully
assess and identify the phase of disease activity before a
proper treatment plan is made; however, a reliable, conve-
nient, and efficient serologic marker is still unavailable.
An acute-phase protein is defined as one whose
plasma concentration increases (positive acute-phase
protein) or decreases (negative acute-phase protein) by
at least 25% during inflammatory disorders.5 Commonly,
serum levels of acute-phase proteins begin to elevate
within a few hours after the initial stimulation and return
to a normal level in a few days. If the etiologic factors
persist, however, this process can be prolonged and
become a chronic reaction.
In our previous work, we explored the spectrum of
plasma proteins in TA patients by means of proteomics
(data not published). Serum amyloid A (SAA), fibrinogen,
complement C4-binding protein (C4BP), C-reactive pro-
tein (CRP), serum amyloid P (SAP), haptoglobin, -acid
glycoprotein (AAG), transthyretin, 1-microglobin (AMG),
and complement fraction C3c and C4a were expressed
more frequently compared with healthy controls. All these
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cause TA is characterized by alterations of acute and
chronic inflammatory reactions in the three layers of the
arterial wall, circulating levels of acute-phase proteins may
change with this pathologic course.
The objectives of this study were to determine whether
the levels of acute-phase proteins were altered in TA pa-
tients in the different activity phases compared with healthy
controls. To the best of our knowledge, this is the first time
that a group of acute-phase proteins have been quantitated
and characterized in TA patients.
MATERIALS AND METHODS
The study protocol was in agreement with the guide-
lines of the Declaration of Helsinki and was approved by
the Ethics Board of the Capital Medical University, Beijing,
China. All participants provided informed consent.
Patients and controls. The study included 43 pro-
spectively selected patients with TA who had been referred
to the Vascular Surgery Department of Anzhen Hospital
affiliated with the Capital Medical University of China from
September 2006 to October 2008. The diagnosis of TA
was based on clinical symptoms, physical examination,
laboratory findings, and angiographic results. The pa-
tients fulfilled the Sharma modified criteria for the clin-
ical diagnosis of TA by a sensitivity of 92.5% and a
specificity of 95%.6
Patients were excluded from the study if they had one
of the following four conditions: (1) a history of autoim-
mune disease, such as systemic lupus erythematosus or
rheumatoid arthritis; (2) a history of trauma or surgical
operation 1 month; (3) a history of cardiovascular or
cerebrovascular event (eg, myocardial infarction or stroke),
or (4) an acute or chronic inflammatory condition, such as
acute bacterial or viral infection, or chronic inflammatory
bowel disease, among others.
Disease activity was evaluated by theNational Institutes
of Health (NIH) criteria.7 Briefly, patients who had new-
onset or worsening of each of the following four features
were scored 1:
1. the presence of systemic features such as fever or mus-
culoskeletal problems (no other cause identified);
2. an elevated erythrocyte sedimentation rate (ESR);
3. the presence of features of vascular ischemia or inflam-
mation, such as claudication, diminished or absent
pulse, bruits, vascular pain (carotodynia), or asymmet-
rical blood pressure in upper or lower limbs; and
4. typical angiographic features.
Patients with a score of 0 or 1 were defined as inactive TA.
Patients with a score of 2, 3, or 4 were defined as active TA.
The vascular lesions of each participant with symptoms
suggestive of an active phase of TA were inspected by
angiography or a computed tomography angiogram. In
other participants, the absence of new vascular lesions was
verified by ultrasound imaging, computed tomography an-
giography, or magnetic resonance angiography According
to the criteria, 18 patients were in the active phase and 25were in the inactive phase when they were registered in the
study. Six patients were receiving medical immunosuppres-
sive therapies by prednisone (1 mg/kg/d), two patients
were receiving a maintenance dose of prednisone (5 to 10
mg/d), and one patient was taking cyclophosphamide
(25 mg/d).
Angiographic features were classified according to the
International TA Conference angiographic classification in
Tokyo 1994 as follows:
● type I—involvement of the main branches from the
aortic arch;
● type IIa—involvement of the ascending aorta, aortic
arch, and its branches;
● type IIb—involvement of the ascending aorta, aortic
arch and its branches, and thoracic descending aorta;
● type III—involvement of any or all of the thoracic
descending aorta, abdominal aorta, or renal arteries;
● type IV—involvement of the abdominal aorta or renal
arteries, or both; and
● type V—the combined features of types IIb and IV.8
The control group consisted of 20 age- and gender-
matched healthy volunteers who were a mean age of
27.45  5.80 years (range, 21-46 years). They had no
clinical history of cardiovascular disease, collagen disease,
or autoimmune disease, and no current inflammatory state.
Their ethnic origins and socioeconomic backgrounds were
similar to the TA participants.
Blood sampling. After an overnight fast, 10 mL of
venous blood was collected in the morning from the medial
cubital vein into a plain sterile tube for serum and into a
heparinized tube for plasma. Serum and plasma were sepa-
rated 1 hour and stored at –80°C until further analysis.
Biochemical laboratory investigations. A baseline
biochemical investigation was initiated in all the partici-
pants, including a hemogram, urine analysis, and blood
biochemistry test. The ESR was also measured using the
Westergreen method.
Test of acute-phase proteins. A commercially avail-
able enzyme-linked immunosorbent assay (ELISA) kit was
used to test SAA, fibrinogen, C4BP, SAP, haptoglobin,
AAG, transthyretin, AMG, and complement fraction C3c
and C4a according to the manufacturer’s instructions (Us-
cnlife Sciences & Technology Co. Ltd Wuhan, China).
CRP was measured by latex agglutination turbidimetric
immunoassay (Uscnlife Sciences & Technology).
Statistical analysis. Data are expressed as mean 
standard deviation (SD) for normally distributed data and
median and interquartile range (IQR) for non-normally
distributed data. Accordingly, analysis of variance and least
significant difference tests, and Kruskal-Wallis and Wil-
coxon rank sum tests were used to compare the differences
between groups, when appropriate. The analysis was con-
ducted with SPSS 13.0 software (SPSS Inc, Chicago, Ill),
and values of P  .05 were considered to be statistically
significant.
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Clinical features of the participants. The clinical
features of the study participants are summarized in Table I.
A total of 43 TA patients with 18 in active phase and 25 in
inactive phase, together with 20 healthy controls, were
included and divided into three groups accordingly. Mean
ages of the active-phase TA, inactive-phase TA, and the
control groups were, respectively, 25.17  7.88, 30.56 
12.04, and 27.45  5.80 years. The female/male ratios of
the TA groups and the control group were 7.6:1 and 9:1,
respectively.
The angiographic classification data indicated that ves-
sels above the aortic arch, including the subclavian, carotid,
and the innominate arteries (type I) were the most com-
monly involved in the TA group (16 of 43), the next
commonest pattern was type V (13 of 43). Nine patients
(21%), six in active phase and three in inactive phase, were
receiving immunosuppressive treatments when the study
began.
Laboratory investigations. ESR was more frequently
Table I. Clinical characteristics of the participants
Demographics Active TA (n  18) In
Age, mean  SD, y 25.17  7.88
Female/male 16:2
Vessel involvement, No. (%)
Type I 7 (16.3)
Type IIa 1 (2.3)
Type IIb 0 (0]
Type III 2 (4.7)
Type IV 2 (4.7)




SD, Standard deviation; TA, Takayasu arteritis.
Table II. Results of laboratory biochemical investigations
Investigations Active TAa (n  18) In
ESR, mm/h 39.1  24.8b,c
Elevated ESR, No. (%) 15 (83.3)
Hemoglobin, g/dL 10.1  1.7b
White blood cells, 109/L 8.2  2.3
Platelets, 109/L 206  53
Fasting blood glucose, mmol/L 4.81  0.92
Urea, mmol/L 5.37  1.52
Creatinine, umol/L 69.6  23.0
Cholesterol
Total, mmol/L 4.42  1.06
Triglyceride, mmol/L 1.14  0.34
LDL, mmol/L 2.10  0.83
HDL, mmol/L 1.71  0.44
ESR, Erythrocyte sedimentation rate; HDL, high-density lipoprotein; LDL
aUnless otherwise indicated, data are expressed as mean  standard deviatio
bP  .05 vs control group.
cP  .05 vs inactive TA group.elevated in active-phase patients (83.3%) than in inactive-phase patients (28%; Table II). The mean ESR was 39.1 
24.8 mm/h in active TA compared with 15.2 9.6 mm/h
in inactive TA (P .001) and 11.3 5.1mm/h in controls
(P  .001). However, a lower hemoglobin level was de-
tected in both TA groups compared with the control group
(10.1  1.7 in active and 10.7  1.4 in inactive vs 13.2 
1.2 g/L in controls, both P  .001). No difference was
noted between groups with respect to the other variables
analyzed.
Levels of acute-phase proteins. This study analyzed
11 acute-phase proteins. The normality of data was tested
by Kolmogorov-Smirnov test. The results of C3c, transthy-
retin, and AMG were normally distributed and are given as
mean  SD. The other results were non-normally distrib-
uted and are given as median (IQR).
Plasma levels of SAAwere significantly raised in patients
with active TA compared with patients with inactive TA
and the controls (95.9 [51.9] vs 49.2 [82.0], P .009 and
23.9 [50.1] mg/L, P  .001, respectively). At the same
time, SAA levels of inactive TA patients were significantly
TA (n  25) Total TA (n  43) Controls (n  20)
6  12.04 28.30  10.74 27.45  5.80
22:3 38:5 18:2
(20.9) 16 (37.2) . . .
(4.7) 3 (7.0) . . .
(4.7) 2 (4.7) . . .
(2.3) 3 (7.0) . . .
(9.3) 6 (14.0) . . .
(16.3) 13 (30.2) . . .
2 8 . . .
1 1 . . .
e TAa (n  25) Total TAa (n  43) Controlsa (n  20)
.2  9.6 25.2  21.0b 11.3  5.1
7 (28) 22 (51.2) 0 (0)
.7  1.4b 10.5  1.6a 13.2  1.2
.3  1.7 8.27  1.99 7.5  1.3
85  51 196  52 201  40
62  0.69 4.71  0.79 5.02  0.80
04  1.72 5.76  1.66 5.43  1.44
.9  24.9 73.9  24.2 67.3  21.4
34  1.28 4.38  1.18 4.92  1.04
05  0.38 1.08  0.36 0.90  0.42
32  0.99 2.23  0.92 2.08  0.65
01  1.07 1.88  0.87 1.84  0.54




















n.higher than that of the controls (49.2 [82.0] vs 23.9 [50.1]
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are shown in Fig 1.
We also observed a significant elevation of C4BP levels
in the plasma of active TA patients (88.5 [72.6] mg/L)
compared with the inactive patients (61.7 [57.7] mg/L,
P .023) and the controls (32.6 [32.1] mg/L P .001).
When the plasma C4BP levels were compared between
patients with inactive TA and the controls, a statistical
difference was still detected (P  .025). The measured
levels of C4BP in the study participants are shown in Fig 2.
Table III gives the results of all the acute-phase protein
levels that were investigated. Except for SAA and C4BP, no
statistical difference between the three groups was found in
the levels of CRP (P  .116), fibrinogen (P  .150),
Fig 1. Scatter plot shows the circulation levels of serum amyloid
A (SAA) in 18 active-phase Takayasu arteritis (TA) patients, 25
inactive-phase TA patients, and 20 healthy controls. The bar
represents the median concentration of each group.
Fig 2. Scatter plot shows the circulation levels of complement
C4-binding protein (C4BP) in 18 active-phase Takayasu arteritis
(TA) patients, 25 inactive-phase TA patients, and 20 healthy
controls. The bar represents the median concentration of each
group.haptoglobin (P .645), AAG (P .110), SAP (P .168),transthyretin (P .112), C3c (P .513), C4a (P .784),
and AMG (P  .193).
DISCUSSION
The etiology and the underlying mechanism of TA are
still far from clarified. Various studies have elucidated the
importance of an immune-mediated mechanism in the
development of TA.9 In the active phase, TA is character-
ized as infiltration of lymphocytes and monocytes in the
arterial wall, and at the same time, large amounts of cyto-
kines and inflammatory factors are released to the circula-
tion. As coming to the inactive phase, degradation of the
elastic layer and fibrosis of the adventitia and media are the
predominant alterations. Most patients with TA experience
one or more cycles from the active phase to remission, then
relapse.
The terms active and inactive are a reflection of differ-
ent inflammatory states on the arterial wall. Accurate eval-
uation of disease activity in TA patients is important to
avoid severe and various side effects from overuse of immu-
nosuppressive drugs. It is also critical for surgeons to deter-
mine an appropriate operation time, because surgical inter-
ventions during the active phase usually cause a higher
reintervention rate and more complications than those
done in the inactive phase.4,10 However, our ability to
assess the disease activity in patients with TA is quite limited
due to the absence of definitive tests for this purpose.11
Acute-phase proteins are a group of liver-derived
plasma proteins induced and regulated by cytokines and
inflammatory factors such as interleukin-6, interleukin-1,
and growth factor.12-15 The concentration of acute-phase
proteins is correlated to the degree and extent of the
inflammatory lesions. Normally, the level rises immediately
after the initiation of the tissue inflammatory reaction, lasts
for a few days, and then returns to normal levels. But the
alteration can be prolonged and converted to a chronic
response if the stimulus or low-grade inflammation con-
tinues.
In clinical practice, levels of acute-phase proteins
are usually investigated to get valuable information on
the presence and degree of inflammatory diseases.16 Some
acute-phase proteins have been considered among the
strongest predictors of cardiovascular events in the general
population and in patients with diabetes.17,18 Because TA
is a typical immune-mediated disease, it is possible that
levels of acute-phase proteins fluctuate with the inflamma-
tory state of the lesions on the vessels. They also may be
useful in the observation of disease activity. To test this
supposition, we investigated the concentration of a group
of acute-phase proteins in patients with TA and healthy
controls.
The clinical data from the 18 active-phase and 25
inactive-phase TA patients included in this study showed
similarities with data from previous reports. First, TA affects
young women more frequently. The mean age in our study
was 28.30 years in the TA group, and the ratio of women to
men was 7.6:1, which was similar to the reports of Korean
(6:1) and Mexican (6.9:1) patients, but lower than that of
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Thai (2.15:1) patients.
Second, the aortic arch and its branches (type I) are
the most frequently involved vessels, which is in accor-
dance with the results of Korean and Japanese studies.
For Indian patients, however, the abdominal aorta or
renal arteries, or both (type V and type IV), are affected
more commonly.
Finally, laboratory investigations show a significant el-
evation of ESR and a mild anemia in TA patients, although
other items are within normal ranges.11 Various types of
autoantibody found in the circulation of TA patients may
accelerate the aging and death of red blood cells and may
explain the anemia found in TA patients.
ESR level was significantly elevated in this group of TA
patients, especially in the active-phase patients. A literature
review found that ESR, one of the most often-used indexes
in TA patients, seems to take an “inconsistent” presenta-
tion. Hall et al19 found that ESR was raised in 78% of 32
patients and correlated well with the corticosteroid treat-
ment. Another report from Korea of 108 TA patients
showed that 96.7% of patients with active disease had an
elevated ESR level compared with 11.8% in those in remis-
sion, and the mean ESR level of the active group was
significantly higher than that of the inactive group.20
Other researchers have drawn a contrary conclusion,
however, and the specificity and sensitivity of ESR are
suspected. In a study from the NIH, ESR was elevated in
almost half of the patients with clinically inactive disease
andwas within a normal range in 28% of patients with active
disease. The authors also found that 40% of the patients
who had been believed to be inactive, with a normal ESR
before the operation, were ultimately confirmed by histo-
pathology to be in an active disease phase.21,22
The data in our study presented a significant eleva-
tion of ESR level in active-phase patients compared with
inactive-phase patients and controls. When analyzing the





Mean  SD N
Serum amyloid A, mg/L 18 95.9 (51.9)
C4BP, mg/L 18 88.5 (72.6)
C-reactive protein, mg/L 18 6.65 (18.1)
Fibrinogen, g/L 18 3.82 (2.26)
Haptoglobin, g/L 18 1.73 (2.53)
-Acid glycoprotein, g/L 18 189.4 (310.3)
Serum amyloid P, mg/L 18 43.3 (65.7)
C4a, mg/L 11 13.3 (13.6)
C3c, mg/L 11 689.8  263
Transthyretin, mg/L 18 148  59.3
1-Microglobin, mg/L 9 2.68  1.41
C3c, Complement fraction C3c; C4a, complement fraction C4a; C4BP, co
TA, Takayasu arteritis.
aValues of P  .05 are statistically significant.data, however, we should not neglect the influencing factorthat the participants were assessed and grouped by the NIH
criteria, in which an elevation of ESR is considered a
criterion. ESR is a nonspecific parameter of inflammation,
and is greatly influenced by multiple factors, such as the
number, size, and shape of erythrocytes, plasma proteins,
and electric charges of the blood cells. It seems that using a
single unique serologic marker such as ESR is not sufficient
in the monitoring of disease activity.
SAA and C4BPmay be supplements to ESR. We found
that the circulation levels of SAA and C4BP in active-phase
patients were significantly higher than those in inactive-
phase patients and in healthy controls, and the levels in the
inactive patients were still higher than those of the controls.
These data indicate that SAA and C4BP may be helpful in
the assessment of disease activity in TA patients.
SAA is the most sensitive acute-phase protein. It has
been reported to be a valuable marker in activity monitor-
ing in inflammatory diseases such as arthritis and pancreati-
tis. SAA rapidly responds to inflammatory stimulus with a
dramatic increase in plasma concentration, sometimes ap-
proaching 1000-fold. Our data did not show such a great
difference between groups, but they varied considerably
among individual patients.
Production of SAA in hepatocytes is mainly regulated
by cytokines such as interleukin-6, interleukin-1, and tu-
mor necrosis factor-. Meanwhile, these cytokines have
been verified to be major members of the complicated
inflammatory factor nets in the pathogenesis of TA. This
may partially explain the elevation of SAA in TA patients.
SAA is also a modulator of immune inflammatory reactions.
In vitro studies indicate that SAA promotes adhesion, mi-
gration, and infiltration of lymphocytes and monocytes,
regulates production of cytokines by inflammatory cells,
and increases the generation of extracellular matrix metal-
loproteinases.23,24 So, SAA may participate in the damage
reaction of the artery wall.
C4BP is a high-molecular-weight plasma glycoprotein
ctive TA group Control group
Pa
Median (IQR) or
Mean  SD No.
Median (IQR) or
Mean  SD
49.2 (82) 20 23.9 (50.1) .001
61.7 (57.7) 20 32.6 (32.1) .001
2.3 (5.75) 20 2.28 (1.58) .116
3.23 (3.95) 20 3.19 (2.77) .15
1.81 (1.72) 20 1.32 (1.69) .654
176.9 (102.6) 20 226.6 (304.4) .11
49.3 (116.9) 20 36.9 (62.7) .168
14.9 (10.4) 10 16 (23.9) .784
780.3  231.9 13 793  225.3 .513
193  95.6 20 149.8  68 .112
2.58  0.96 9 2.48  1.27 .193













mplemstructurally composed of six or seven identical -chains and
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to fourfold in immune-mediated diseases such as systemic
lupus erythematosus, nephrotic syndrome, solid tumors,
and acute pneumonia. C4BP is synthesized in liver cells,
also under the regulation of proinflammatory factors. Mul-
tifunction of C4BP has been found, including inhibiting
the activation of classical and lectin pathway of comple-
ments, modulating anticoagulation activity of protein S,
and sustaining the survival of B lymphocytes. The function
and significance of C4BP in the pathogenesis of TA patients
is waiting for further study.
CRP is not a reliable index for activity assessment in TA
patients according to our data, a conclusion that is also
supported by previous studies.25,26 Other acute-phase pro-
teins tested in this study, including fibrinogen, SAP, hap-
toglobin, transthyretin, AAG, AMG, C3c, and C4a did not
show activity-correlating alterations in the plasma levels.
However, considering this is a trans-section study at a
single point of time, we could not rule out the possibility
that these acute-phase proteins can be used as a biomarker
longitudinally in individual patients.
A primary limitation of this study is that used a scoring
system to identify disease activity instead of the gold stan-
dard of histopathology. This was because obtaining patho-
logic specimens from TA patients is impractical in most
cases. Another limitation is that six patients of the active-
phase group were receiving immunosuppressive therapy
when the blood samples were collected, and these agents
might have an influence on the synthesis of proteins in
hepatocytes.
CONCLUSIONS
We examined the plasma concentrations of 11 kinds of
acute-phase proteins in TA patients in different phases of
disease activity and in controls. To the best of our knowl-
edge, this is the first study to characterize circulating acute-
phase proteins rather than only ESR and CRP in a cohort of
TA patients. The levels of SAA and C4BP in active-phase
patients were significantly higher than those in inactive-
phase patients and controls. The levels in inactive TA
patients are still higher than that of controls. SAA and
C4BP may be useful for the diagnosis and activity discrim-
ination of patients with TA. These results are still waiting
for further testing by a larger group of patients in longitu-
dinal manner.
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